Biotechs Eye Macular Degeneration

Spurred by the commercial success of Lucentis, start-ups developing new therapeutics for AMD tap into a growing understanding of the pathogenesis of the disease. In this issue, we profile five emerging AMD drug developers: Acucela, Iconic Therapeutics, MacuCLEAR, Ophthotech, Optherion and Sirion Therapeutics.

It has been three years since Roche’s Genentech Inc. launched its vascular endothelial growth factor (VEGF) inhibitor ranibizumab (Lucentis), quickly capturing the lion’s share of the market for wet age-related macular degeneration (AMD) from competing treatments such as QLT Inc.’s photodynamic therapy verteporfin (Visudyne) and Pfizer Inc./OSI Pharmaceuticals LLC’s anti-VEGF treatment pegaptanib (Macugen). Lucentis’s rapid adoption by ophthalmologists—in 2008 the drug racked up sales totaling $875 million in the US alone—illustrates the importance of having a clinically superior therapy.

With a highly effective therapy on the market for AMD—Genentech’s antibody fragment stops progression of AMD in virtually all patients...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip